Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 17/20 | 0.69 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10106426 | 1.00 | GPR119 (0.69) | GPR119SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL10120596 | 0.96 | GPR119 (0.67) | GPR119SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL10121122 | 0.92 | GPR119 (0.69) | GPR119 | |
| SCHEMBL10120603 | 0.92 | GPR119 (0.69) | GPR119 | |
| SCHEMBL14668822 | 0.89 | GPR119 (0.57) | GPR119SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL16281377 | 0.89 | GPR119 (0.57) | GPR119SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL12320073 | 0.89 | GPR119 (0.57) | GPR119SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL16281378 | 0.89 | GPR119 (0.55) | GPR119SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL14668823 | 0.89 | GPR119 (0.55) | GPR119SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL12320005 | 0.89 | GPR119 (0.55) | GPR119SLC6A2SLC6A3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8907095-B2 | Bicyclic heterocycle derivatives and their use as modulators of the activity of GPR119 | MERCK SHARP & DOHME CORP. (US) | 2014-12-09 | — | — | US | disclosed |
| US-20110212938-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND THEIR USE AS MODULATORS OF THE ACTIVITY OF GPR119 | SCHERING CORPORATION | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212938-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND THEIR USE AS MODULATORS OF THE ACTIVITY OF GPR119 | GPR119, GPR88, GPR180 | GPR119 1/4885SLC6A2 2518/4885SLC6A3 2805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.